YES1

Overview

YES1 (YES proto-oncogene 1, Src family tyrosine kinase) is a non-receptor tyrosine kinase of the SRC family involved in cell proliferation, survival, and migration. In oral squamous cell carcinoma (OSCC), YES1 is one of three SRC-family kinases (SRC, LYN, YES1) collectively altered via copy gain in approximately 29% of tumors, nominating the SRC kinase family as a candidate therapeutic axis.

Alterations observed in the corpus

Part of a set of SRC-family kinases (SRC, LYN, YES1) collectively altered (copy gain with high expression) in 29% (10/35) of OSCC tumors PMID:23619168.
Identified as a novel amplification target in lung cancer in the TCGA Pan-Lung comprehensive genomic characterization of 1,144 NSCLC cases PMID:27158780.

Cancer types (linked)

OSCC: SRC-family kinase copy gain is a recurring event; YES1 is one of three SRC-family members collectively altered in ~29% of oral squamous cell carcinoma cases PMID:23619168.
LUAD / LUSC: Novel amplification target in lung cancer identified by the TCGA Pan-Lung study PMID:27158780.

Co-occurrence and mutual exclusivity

Co-altered with SRC and LYN as part of the broader SRC-family kinase gain landscape in OSCC; Aurora kinases (AURKA, AURKC) were altered in an additional 14% (5/35) of the same cohort PMID:23619168.

Therapeutic relevance

SRC-family kinase inhibitors are in clinical use or development; the 29% collective SRC-family alteration rate in OSCC (including YES1) provides genomic rationale for their evaluation, though OSCC-specific clinical data were not reported in this study PMID:23619168.

Open questions

Whether YES1 specifically (vs. SRC or LYN) is the functional driver in individual OSCC tumors with 3-way SRC-family gain is undetermined; copy gain with high expression was used as the discovery criterion, not functional validation PMID:23619168.

Sources

This page was processed by entity-page-writer on 2026-05-15.